The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.
Locally Advanced Breast Cancer|Metastatic Breast Cancer
DRUG: Fulvestrant|DRUG: Exemestane
Time to disease progression (TTP), after 580 Progression events accrued
Objective response rate, after 580 Progression events accrued|Overall survival, after 580 Progression events accrued|Duration of response, after 580 Progression events accrued|Clinical Benefit, after 580 Progression events accrued|Quality of Life, after 580 Progression events accrued|PK, each visit|Safety and tolerability., after 580 Progression events accrued
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.